<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005065</url>
  </required_header>
  <id_info>
    <org_study_id>IN_BTK_102</org_study_id>
    <nct_id>NCT05005065</nct_id>
  </id_info>
  <brief_title>Evaluation of the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 and IN-A001 in Healthy Caucasians</brief_title>
  <official_title>A Randomized, Open-label, Multiple Dosing, Cross-over Phase 1 Clinical Trial to Evaluate Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 and IN-A001 After Oral Administration in Healthy Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pharmacokinetics/pharmacodynamics and&#xD;
      safety/tolerability of IN-C005 and IN-A001 after oral administration in healthy Caucasian&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Part 1] To evaluate the pharmacokinetic (PK)/pharmacodynamic (PD) profiles and&#xD;
      safety/tolerability of 100 mg IN-C005 versus 100 mg IN-A001 after multiple oral dosing in&#xD;
      healthy Caucasian subjects&#xD;
&#xD;
      [Part 2] To evaluate the PK/PD profiles and safety/tolerability of 50 mg IN-C005 versus 75 mg&#xD;
      IN-C005 after multiple oral dosing in healthy Caucasian subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, open-label, multiple dosing, crossover study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1, Day 22</time_frame>
    <description>PK: Maximum concentration of drug in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>Day 1, Day 22</time_frame>
    <description>PK: Area under the plasma drug concentration-time curve from 0 to last point of measurable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>Day 7 and Day 28</time_frame>
    <description>PK: Maximum (peak) steady-state plasma drug concentration during a dosage interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau,ss</measure>
    <time_frame>Day 7 and Day 28</time_frame>
    <description>PK: Area under the plasma drug concentration-time curve for a dosing interval at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent duration of pH ≥4 in 24 hrs (duration %)</measure>
    <time_frame>Day 1, Day 22</time_frame>
    <description>PD: pH parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent duration of pH ≥4 in 24 hrs (duration %)</measure>
    <time_frame>Day 7, Day 28</time_frame>
    <description>PD: pH parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in percent duration of pH ≥4 in 24 hrs</measure>
    <time_frame>Day 1, Day 7, Day 22, Day 28</time_frame>
    <description>PD: pH parameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Day 1, Day 22</time_frame>
    <description>PK: Area under the plasma drug concentration-time curve from time 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1, Day 22</time_frame>
    <description>PK: The time of peak concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Day 1, Day 22</time_frame>
    <description>PK: Terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Day 1, Day 22</time_frame>
    <description>PK: Apparent Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>Day 1, Day 22</time_frame>
    <description>PK: Apparent volume of distribution after extravascular administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss</measure>
    <time_frame>Day 7, Day 28</time_frame>
    <description>PK: Time to reach Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss</measure>
    <time_frame>Day 7, Day 28</time_frame>
    <description>PK: Apparent first order terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss</measure>
    <time_frame>Day 7, Day 28</time_frame>
    <description>PK: Minimum observed non zero concentration between dose time and dose time + dosing interval, tau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cavg,ss</measure>
    <time_frame>Day 7, Day 28</time_frame>
    <description>PK: The average concentration at steady state, calculated as the ratio of AUCtau to the dosing interval, tau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/F</measure>
    <time_frame>Day 7, Day 28</time_frame>
    <description>PK: The total body clearance at steady state after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd,ss/F</measure>
    <time_frame>Day 7, Day 28</time_frame>
    <description>PK: Apparent volume of distribution after extravascular administration in steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTF</measure>
    <time_frame>Day 7, Day 28</time_frame>
    <description>PK: Peak to trough fluctuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R</measure>
    <time_frame>Day 7, Day 28</time_frame>
    <description>PK: Accumulation ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent duration of pH ≥3 in 24 hrs</measure>
    <time_frame>Day 1, Day 7, Day 22, Day 28</time_frame>
    <description>PD: pH parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in percent duration of pH ≥3 in 24 hrs</measure>
    <time_frame>Day 1, Day 7, Day 22, Day 28</time_frame>
    <description>PD: pH parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent duration of pH ≥6 in 24 hrs</measure>
    <time_frame>Day 1, Day 7, Day 22, Day 28</time_frame>
    <description>PD: pH parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in percent duration of pH ≥6 in 24 hrs</measure>
    <time_frame>Day 1, Day 7, Day 22, Day 28</time_frame>
    <description>PD: pH parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and median pH in 24 hrs</measure>
    <time_frame>Day 1, Day 7, Day 22, Day 28</time_frame>
    <description>PD: pH parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean pH in 24 hrs</measure>
    <time_frame>Day 1, Day 7, Day 22, Day 28</time_frame>
    <description>PD: pH parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in median pH in 24 hrs</measure>
    <time_frame>Day 1, Day 7, Day 22, Day 28</time_frame>
    <description>PD: pH parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEGlast</measure>
    <time_frame>Day 1, Day 7, Day 22, Day 28</time_frame>
    <description>PD(Gastrin): Area under the concentration-time curve of Serum Gastrin from 0 to last point of quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gmax</measure>
    <time_frame>Day 1, Day 7, Day 22, Day 28</time_frame>
    <description>Gastrin: Maximum gastrin level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ΔAUEGlast</measure>
    <time_frame>Day 1, Day 7, Day 22, Day 28</time_frame>
    <description>PD(Gastrin): Change from baseline in AUEGlast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ΔGmax</measure>
    <time_frame>Day 1, Day 7, Day 22, Day 28</time_frame>
    <description>PD(Gastrin): Change from baseline in Gmax</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment AB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive IN-C005 Y mg (Treatment A) and IN-A001 Y mg (Treatment B) sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment BA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive IN-A001 Y mg and IN-C005 Y mg sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment CD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive IN-C005 Z mg (Treatment C) and IN-C005 X mg (Treatment D) sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment DC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive IN-C005 X mg and IN-C005 Z mg sequentially in a two-period sequence. There will be a washout period of at least 14 days between Period 1 and Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-C005 X mg</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Treatment CD</arm_group_label>
    <arm_group_label>Treatment DC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-A001 Y mg</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Treatment AB</arm_group_label>
    <arm_group_label>Treatment BA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-C005 Y mg</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Treatment AB</arm_group_label>
    <arm_group_label>Treatment BA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-C005 Z mg</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Treatment CD</arm_group_label>
    <arm_group_label>Treatment DC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is healthy Caucasian adult aged 19 to 50 years (inclusive) at the time of signing the&#xD;
             informed consent form (ICF) (A Caucasian is defined as a European who was born in&#xD;
             Europe, has the duration of residence outside of Europe less than 10 years, and both&#xD;
             of whose parents and grandparents are European-born).&#xD;
&#xD;
          2. Has ≥ 18.0 and ≤ 30.0 kg/m2 of body mass index (BMI) with a body weight (BW) ≥ 55.0 kg&#xD;
             at screening.&#xD;
&#xD;
          3. Has a negative result in serum Helicobacter pylori IgG antibody test.&#xD;
&#xD;
          4. Decides to participate voluntarily in the study after being fully informed of and&#xD;
             understanding the study completely, and provides his/her written informed consent&#xD;
             prior to screening procedure.&#xD;
&#xD;
          5. Is eligible for this study in the opinion of the investigator based on the results of&#xD;
             physical examination, clinical laboratory tests, interview, etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a history or current evidence of clinically significant disorder of hepatic,&#xD;
             renal, nervous, respiratory, endocrine, hemato-oncologic, cardiovascular, urinary,&#xD;
             and/or psychiatric system.&#xD;
&#xD;
          2. Has a history or current evidence of gastrointestinal disease that may affect the&#xD;
             safety and PD assessments for study treatment (e.g., gastrointestinal ulcer,&#xD;
             gastritis, gastric cramp, gastroesophageal reflux disease, and Crohn's disease) or a&#xD;
             history of gastrointestinal surgery (except for simple appendectomy or herniotomy).&#xD;
&#xD;
          3. Has a history or current evidence of clinically significant hypersensitivity to study&#xD;
             drugs or any ingredient of proton pump inhibitors and other drugs (such as aspirin and&#xD;
             antibiotics).&#xD;
&#xD;
          4. Has a positive result on serology tests (for hepatitis B, human immunodeficiency virus&#xD;
             [HIV], and hepatitis C).&#xD;
&#xD;
          5. Has a blood level of total bilirubin, AST (GOT), or ALT (GPT) &gt; 1.5 X upper limit of&#xD;
             normal (ULN) based on screening procedures including repeated ones.&#xD;
&#xD;
          6. Has a calculated eGFR per MDRD equation &lt; 60 mL/min/1.73 m2 based on screening&#xD;
             procedures including repeated ones.&#xD;
&#xD;
          7. Has systolic blood pressure (SBP) of &lt; 90 mmHg or &gt; 140 mmHg, diastolic blood pressure&#xD;
             (DBP) of &lt; 50 mmHg or &gt; 95 mmHg, or pulse rate (PR) of &lt; 45 beats/min or &gt; 100&#xD;
             beats/min on vital signs as measured in sitting position after taking a rest for at&#xD;
             least 5 minutes at screening.&#xD;
&#xD;
          8. Has an anatomical disorder that precludes insertion and maintenance of intragastric pH&#xD;
             meter catheter or is expected to be intolerable to insertion of intragastric pH meter&#xD;
             catheter.&#xD;
&#xD;
          9. Has a history of drug abuse or has a positive response to drug abuse on urine drug&#xD;
             screening test.&#xD;
&#xD;
         10. Has received any prescription drug or herbal medication within 2 weeks of or any&#xD;
             over-the-counter (OTC) drug, dietary supplements, or vitamins within 1 week of&#xD;
             scheduled first dose or is expected to receive such medication during the study (Note:&#xD;
             a subject may participate in the study at the discretion of the investigator provided&#xD;
             the subject meets all the other criteria).&#xD;
&#xD;
         11. Has participated and received an investigational agent in another clinical trial or&#xD;
             bioequivalence study within 6 months prior to the first dose of study treatment (Note:&#xD;
             This is not applied to participation in another part of this study).&#xD;
&#xD;
         12. Has donated whole blood within 2 months prior to the scheduled first dose, or has&#xD;
             donated blood components or received transfusion within a month prior to the scheduled&#xD;
             first dose.&#xD;
&#xD;
         13. Has excessive caffeine intake (&gt; 5 units/day), continues the use of alcohol (&gt; 21&#xD;
             units/week, 1 unit = 10 g of pure alcohol), or is unable to stop drinking during&#xD;
             hospitalization period.&#xD;
&#xD;
         14. Has a positive result for cotinine on urine drug screening test or is unable to stop&#xD;
             smoking throughout the study.&#xD;
&#xD;
         15. Is unable to avoid grapefruit-containing foods during the time from 24 hours (hrs)&#xD;
             before hospitalization to discharge in Period 1 and Period 2, respectively.&#xD;
&#xD;
         16. Is unable to avoid caffeine-containing foods (e.g., coffee, tea [red tea, green tee,&#xD;
             etc.], soda, coffee milk, and nutritive tonic drink) during the time from 24 hrs&#xD;
             before hospitalization to discharge Period 1 and Period 2, respectively.&#xD;
&#xD;
         17. For all women of childbearing potential (WOCBP) excluding those on amenorrhea for at&#xD;
             least 12 months and those who underwent surgical sterilization (bilateral tubal&#xD;
             ligation, bilateral oophorectomy, or hysterectomy), has a positive result for&#xD;
             pregnancy test (urine hCG) performed prior to the first dose of study treatment or is&#xD;
             pregnant or breastfeeding.&#xD;
&#xD;
         18. Is unable to use a medically acceptable contraceptive method throughout the study.&#xD;
             Medically acceptable contraceptive methods include:&#xD;
&#xD;
               -  Use of an intrauterine device with a proven birth control failure rate by the&#xD;
                  subject or subject's spouse (or partner)&#xD;
&#xD;
               -  Use of (male or female) barrier method with spermicide&#xD;
&#xD;
               -  Surgical sterilization (vasectomy, salpingectomy, tubal ligation, hysterectomy)&#xD;
                  of the subject or subject's spouse (or partner)&#xD;
&#xD;
         19. Is determined ineligible for study participation by the investigator for other reasons&#xD;
             such as clinical laboratory abnormalities.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology and Therapeutics, Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sun Young Wang</last_name>
    <phone>+82-2-6477-0286</phone>
    <email>sy.wang@inno-n.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Yeon Nam</last_name>
    <phone>+82-2-6477-0277</phone>
    <email>jy.nam@inno-n.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

